Summary of the technology
Twist GAIN-of-function and LOSS-of-function cell models were developed and used for preclinical p53:MDM2 inhibitors evaluation, preliminary demonstrating that the expression of Twist hampers their efficacy.
These findings support patient stratification on the basis of twist expression for treatment of a large fraction of sarcomas but also of a fraction of carcinomas. (Piccinin et al., Cancer Cell, 22, 404-415, Sept 11 2012).
Current development status
3 different cell lines were consistently characterized.
2 more cell lines are producing promising results.
6 different drugs have already been tested including nutlin3a - AMG 232 - RG7112 - SAR405838.
More than 100 cell vitality tests have been performed.
Currently the knowhow related to the technology is secret. The best IPR protection strategy is under evaluation.
National Cancer Institute CRO Aviano
Additional information (attached documents)